Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Chronic Heart Failure

  Free Subscription


11.02.2019

1 Am Heart J
1 Am J Cardiol
2 Cardiovasc Res
1 Circulation
1 Eur Heart J
12 Eur J Heart Fail
4 Heart
1 Int J Cardiol
1 J Am Coll Cardiol
2 J Card Fail
1 J Cardiol
1 Lancet Diabetes Endocrinol
2 N Engl J Med
2 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am Heart J

  1. ALVI RM, Afshar M, Neilan AM, Tariq N, et al
    Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center.
    Am Heart J. 2019;210:39-48.
    PubMed     Text format     Abstract available


    Am J Cardiol

  2. SARDANA M, Konda P, Hashmath Z, Oldland G, et al
    Usefulness of Left Ventricular Strain by Cardiac Magnetic Resonance Feature-Tracking to Predict Cardiovascular Events in Patients With and Without Heart Failure.
    Am J Cardiol. 2019 Jan 25. pii: S0002-9149(19)30117.
    PubMed     Text format     Abstract available


    Cardiovasc Res

  3. MEIJERS WC, de Boer RA
    Common risk factors for heart failure and cancer.
    Cardiovasc Res. 2019 Feb 4. pii: 5306334. doi: 10.1093.
    PubMed     Text format     Abstract available

  4. ENDOH M
    SERCA in heterogeneity of diastolic dysfunction in post-infarction heart failure with reduced ejection fraction.
    Cardiovasc Res. 2019 Jan 31. pii: 5305030. doi: 10.1093.
    PubMed     Text format    


    Circulation

  5. LEE DP, Tan WLW, Anene-Nzelu CG, Lee CJM, et al
    A Robust CTCF-Based Chromatin Architecture Underpins Epigenetic Changes in the Heart Failure Stress-Gene Response.
    Circulation. 2019 Feb 5. doi: 10.1161/CIRCULATIONAHA.118.036726.
    PubMed     Text format     Abstract available


    Eur Heart J


  6. Heart Failure and Sepsis: Cardiologists have developed a new 'risk profile' tool to identify heart failure patients at risk of dying from sepsis. Mark Nicholls reports.
    Eur Heart J. 2019;40:409-410.
    PubMed     Text format    


    Eur J Heart Fail

  7. LECLERCQ C, Galand V, Behar N, Martins R, et al
    I had a dream....
    Eur J Heart Fail. 2018;20:1482-1484.
    PubMed     Text format    

  8. COSMI F, Staszewsky L, McMurray JJV, Latini R, et al
    Risk stratification according to insulin type: reply.
    Eur J Heart Fail. 2018;20:1498.
    PubMed     Text format    

  9. SKELIN M, Lucijanic M, Javor E
    Risk stratification according to insulin type.
    Eur J Heart Fail. 2018;20:1497.
    PubMed     Text format    

  10. OBOKATA M, Borlaug BA
    Left atrial dysfunction: the next key target in heart failure with preserved ejection fraction.
    Eur J Heart Fail. 2019 Feb 8. doi: 10.1002/ejhf.1420.
    PubMed     Text format    

  11. AMBROSY AP, Lee KK
    Applying data science approaches to identify frequent flyers in heart failure: rise of the machines.
    Eur J Heart Fail. 2019 Feb 7. doi: 10.1002/ejhf.1387.
    PubMed     Text format    

  12. DE BOER RA, De Keulenaer G, Bauersachs J, Brutsaert D, et al
    Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology.
    Eur J Heart Fail. 2019 Feb 4. doi: 10.1002/ejhf.1406.
    PubMed     Text format     Abstract available

  13. GRODIN JL, Philips S, Mullens W, Nijst P, et al
    Prognostic implications of plasma volume status estimates in heart failure with preserved ejection fraction: insights from TOPCAT.
    Eur J Heart Fail. 2019 Feb 4. doi: 10.1002/ejhf.1407.
    PubMed     Text format     Abstract available

  14. BAYES-GENIS A, Lupon J, Nunez J
    No need for urgent revisiting of kalaemia levels in guidelines despite use of mineralocorticoid receptor antagonists: bring in more evidence.
    Eur J Heart Fail. 2018;20:1252-1254.
    PubMed     Text format    

  15. TER MAATEN JM, Damman K
    Chloride, what else?
    Eur J Heart Fail. 2018;20:1444-1446.
    PubMed     Text format    

  16. BORIANI G, Diemberger I
    Cardiac resynchronization therapy in the real world: need to upgrade outcome research.
    Eur J Heart Fail. 2018;20:1469-1471.
    PubMed     Text format    

  17. SINAGRA G, Merlo M, Cannata A
    Gender medicine in dilated cardiomyopathy: pride and prejudice.
    Eur J Heart Fail. 2018;20:1401-1403.
    PubMed     Text format    

  18. CAPTUR G, Bilinska Z, Arbustini E
    Lamin missense mutations-the spectrum of phenotype variability is increasing.
    Eur J Heart Fail. 2018;20:1413-1416.
    PubMed     Text format    


    Heart

  19. CHOUSOU PA, Pugh PJ
    How to deliver optimal cardiac resynchronisation therapy.
    Heart. 2018;104:1300-1307.
    PubMed     Text format    

  20. HUTCHINGS DC, Anderson SG, Caldwell JL, Trafford AW, et al
    Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
    Heart. 2018;104:1244-1250.
    PubMed     Text format     Abstract available

  21. EZEKOWITZ JA
    Creating order out of chaos: quality of care in heart failure.
    Heart. 2019 Jan 31. pii: heartjnl-2018-314526. doi: 10.1136/heartjnl-2018-314526
    PubMed     Text format    

  22. BURDEN AF, Timpson N
    Ethnicity, heart failure, atrial fibrillation and diabetes: collider bias.
    Heart. 2019 Feb 6. pii: heartjnl-2018-314467. doi: 10.1136/heartjnl-2018-314467.
    PubMed     Text format    


    Int J Cardiol

  23. KASSAB GS, Choy JS, Guccione JM
    Reply to Letter to Editor by S Tong, L Zhang, J Joseph, and X Jiang "A potential and novel therapeutic approach to ischemic heart failure: Algisyl-LVR".
    Int J Cardiol. 2019;279:133.
    PubMed     Text format    


    J Am Coll Cardiol

  24. MCHUGH K, DeVore AD, Wu J, Matsouaka RA, et al
    Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review.
    J Am Coll Cardiol. 2019;73:602-611.
    PubMed     Text format     Abstract available


    J Card Fail

  25. HUYNH QL, Whitmore K, Negishi K, Marwick TH, et al
    Influence of Risk on Reduction of Readmission and Death by Disease Management Programs in Heart Failure.
    J Card Fail. 2019 Feb 1. pii: S1071-9164(18)31057.
    PubMed     Text format     Abstract available

  26. SOLOVEVA A, Kobalava Z, Fudim M, Ambrosy AP, et al
    Relationship of Liver Stiffness with Congestion in Patients Presenting with Acute Decompensated Heart Failure.
    J Card Fail. 2019 Feb 2. pii: S1071-9164(18)30338.
    PubMed     Text format     Abstract available


    J Cardiol

  27. SATO Y, Yoshihisa A, Oikawa M, Nagai T, et al
    Prognostic impact of chronic obstructive pulmonary disease on adverse prognosis in hospitalized heart failure patients with preserved ejection fraction - A report from the JASPER registry.
    J Cardiol. 2019 Feb 1. pii: S0914-5087(19)30010.
    PubMed     Text format     Abstract available


    Lancet Diabetes Endocrinol

  28. STORK S
    Renal effects of sacubitril/valsartan in patients with diabetes.
    Lancet Diabetes Endocrinol. 2018;6:519-521.
    PubMed     Text format    


    N Engl J Med

  29. WIVIOTT SD, Raz I, Bonaca MP, Mosenzon O, et al
    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1812389.
    PubMed     Text format     Abstract available

  30. JARCHO J
    PIONEERing the In-Hospital Initiation of Sacubitril-Valsartan.
    N Engl J Med. 2019;380:590-591.
    PubMed     Text format    


    PLoS One

  31. SEID MA, Abdela OA, Zeleke EG
    Adherence to self-care recommendations and associated factors among adult heart failure patients. From the patients' point of view.
    PLoS One. 2019;14:e0211768.
    PubMed     Text format     Abstract available

  32. SANDSTEDT M, Rotter Sopasakis V, Lundqvist A, Vukusic K, et al
    Hypoxic cardiac fibroblasts from failing human hearts decrease cardiomyocyte beating frequency in an ALOX15 dependent manner.
    PLoS One. 2018;13:e0202693.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: